Biogen Inc. (BIIB), based in Cambridge, Massachusetts, is a leading biotechnology company focused on developing and ...

Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Biogen Inc. (BIIB)股价跌至52周新低139.7美元，反映出这家生物科技公司市场表现的显著下滑。根据 InvestingPro 分析，尽管近期面临挑战，但该公司目前203.8亿美元的市值和12.6的市盈率表明其股票可能被低估。过去一年，公司股价从此前位置大幅下跌42.83%，引发投资者担忧。据 InvestingPro ...

Fibonacci (Fib) pullback support levels are at $132.04, $125.00, $115.03, and $105.49. BIIB stock’s average consensus price target is 54.35% higher at $211.96, and its highest analyst price ...

The company's stock has experienced significant volatility over the past year, reflecting investor uncertainty about its future prospects. This comprehensive analysis examines Biogen's current ...

Biogen shares fell, after the biotechnology company forecast lower-than-expected revenue and profit for this year, saying multiple-sclerosis drug sales will decline further and will only be partially ...

Biogen (NASDAQ:BIIB) shares traded flat in the premarket on Wednesday after the Alzheimer’s drug developer reported better-than-expected Q4 2024 financials while its full-year outlook ...

The company's stock has experienced significant volatility over the past year, reflecting investor uncertainty about its future prospects. This comprehensive analysis examines Biogen's current ...